济川药业：多元化中药龙头产品梯队稳步贡献业绩

国联证券2025-04-16

投资要点多元化布局的中药领军企业公司为多元化布局的中药领军企业，产品涵盖清热解毒类、儿科类、消化类、呼吸类等领域，核心大单品为蒲地蓝消炎口服液、小儿豉翘清热颗粒。2019-2023 年公司营收CAGR 达6.8%，归母净利润CAGR 达11.7%，净利率从23.4%提升至29.3%；2024 前三季度业绩承压主要受2023 年同期高基数影响，我们认为随着高基数影响逐步消退，丰富的产品梯队逐步贡献...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2527252396?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-16 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2527252396","market":"sh","top_or_hot":-1,"title":"济川药业：多元化中药龙头 产品梯队稳步贡献业绩","media":"国联证券","content":"<div>\n<p>投资要点多元化布局的中药领军企业公司为多元化布局的中药领军企业，产品涵盖清热解毒类、儿科类、消化类、呼吸类等领域，核心大单品为蒲地蓝消炎口服液、小儿豉翘清热颗粒。2019-2023 年公司营收CAGR 达6.8%，归母净利润CAGR 达11.7%，净利率从23.4%提升至29.3%；2024 前三季度业绩承压主要受2023 年同期高基数影响，我们认为随着高基数影响逐步消退，丰富的产品梯队逐步贡献...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416160645a45acdb2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>济川药业：多元化中药龙头 产品梯队稳步贡献业绩</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n济川药业：多元化中药龙头 产品梯队稳步贡献业绩\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-16 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416160645a45acdb2&s=b><strong>国联证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>投资要点多元化布局的中药领军企业公司为多元化布局的中药领军企业，产品涵盖清热解毒类、儿科类、消化类、呼吸类等领域，核心大单品为蒲地蓝消炎口服液、小儿豉翘清热颗粒。2019-2023 年公司营收CAGR 达6.8%，归母净利润CAGR 达11.7%，净利率从23.4%提升至29.3%；2024 前三季度业绩承压主要受2023 年同期高基数影响，我们认为随着高基数影响逐步消退，丰富的产品梯队逐步贡献...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416160645a45acdb2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416160645a45acdb2&s=b","article_id":"2527252396","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416160645a45acdb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2527252396","pubTimestamp":1744732800,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"投资要点多元化布局的中药领军企业公司为多元化布局的中药领军企业，产品涵盖清热解毒类、儿科类、消化类、呼吸类等领域，核心大单品为蒲地蓝消炎口服液、小儿豉翘清热颗粒。绝对估值测得公司每股价值为34.29 元，可比公司2025 年平均PE 为16 倍，鉴于公司为多元化布局的中药领军企业，首次覆盖，给予“买入”评级。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600566":"济川药业","BK0012":"证金概念","BK0188":"融资融券","BK0077":"质押式回购","BK0239":"医药制造","BK0187":"一线龙头","BK0028":"国家队","BK0201":"可转债"},"translate_title":"Jichuan Pharmaceutical: Diversified echelon of leading Chinese medicine products steadily contributes to performance","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600566":1},"content_text":"投资要点多元化布局的中药领军企业公司为多元化布局的中药领军企业，产品涵盖清热解毒类、儿科类、消化类、呼吸类等领域，核心大单品为蒲地蓝消炎口服液、小儿豉翘清热颗粒。2019-2023 年公司营收CAGR 达6.8%，归母净利润CAGR 达11.7%，净利率从23.4%提升至29.3%；2024 前三季度业绩承压主要受2023 年同期高基数影响，我们认为随着高基数影响逐步消退，丰富的产品梯队逐步贡献业绩增量，公司业绩有望恢复稳定增长。政策赋能中药发展，公司为细分龙头公司两大单品聚焦清热解毒和儿科中药赛道，2023 年中国清热解毒类中药市场317.6 亿元，2018-2023 年CAGR 3.6%，蒲地蓝为最大品种，2023 年销售规模47.5亿元，公司产品市占率62%，为绝对龙头；2023 年儿科感冒中药市场62.4 亿元，2018-2023 年CAGR 达12.2%，公司独家产品小儿豉翘为最大品种，2023 年销售占比46.6%。政策驱动中医诊疗量占比持续提升，从2017 年15.9%提升至2023 年18.8%，随着中医药支持政策不断落地，公司聚焦的中药细分赛道有望持续扩容。打造产品梯队逐步贡献业绩公司20 亿以上量级的两大单品贡献稳定现金流，其中蒲地蓝随着纳入双跨品种，院外市场品牌推广逐步铺开，院外销售有望得到提振；小儿豉翘随着公司加强学术推广以及品牌建设，糖浆剂型获批且进入医保有望补充颗粒剂型空白市场，销售有望维持稳定。呼吸类和消化类二线产品有望补足增长驱动力。外延方面，公司流感药物成人适应在NDA 阶段，我们预计有望在2025Q2 获批；长效生长激素目前在BLA 阶段，BD 项目有望逐步实现商业化贡献业绩增量。中药龙头企业，给予“买入”评级我们预计公司2024-2026 年营业收入分别为81.36/81.54/86.34 亿元，同比增速分别-15.73%/0.22%/5.88%；归母净利润分别为25.25/25.98/28.22 亿元，同比增速分别为-10.55%/2.88%/8.62%，EPS 分别为2.74/2.82/3.06 元/股。绝对估值测得公司每股价值为34.29 元，可比公司2025 年平均PE 为16 倍，鉴于公司为多元化布局的中药领军企业，首次覆盖，给予“买入”评级。风险提示：政策风险、毛利率下滑或波动、产品质量问题、研发和销售不及预期等","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527252396","isCrawlerRequest":true}

济川药业：多元化中药龙头 产品梯队稳步贡献业绩

精彩评论

济川药业：多元化中药龙头产品梯队稳步贡献业绩